Coherus Biosciences (CHRS) AI Stock Analysis

• Market Cap: $127.49M
• Dividend Yield: N/A
• Average Volume (3M): 1.86M
• Price to Earnings (P/E): 6.3
• Beta (1Y): 1.64
• Revenue Growth: 3.78%
• EPS Growth: N/A
• Country: US
• Employees: 228
• Sector: Healthcare
• Sector Strength: 57
• Industry: Biotechnology
• EPS (TTM): 0.17
• Shares Outstanding: 115,896,850
• 10 Day Avg. Volume: 1,537,933
• 30 Day Avg. Volume: 1,860,657
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 2.60
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 2.22
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $5.02
• Price Target Upside: 356.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Coherus Biosciences presents a mixed outlook with significant strengths in revenue growth and strategic initiatives like debt reduction and pipeline expansion. However, financial instability due to zero stockholders' equity and operational cash flow challenges pose risks. The technical analysis indicates moderate momentum, and the stock appears undervalued, offering potential upside if financial issues are resolved.

Positive Factors

Clinical Trials

A confirmed partial responder in a high-dose cohort of CHS-114/toripalimab potentially points to a new treatment paradigm in highly refractory HNSCC.

Financial Performance

The company reported an annual net revenue increase, with 4Q revenue beating market expectations, indicating strong financial performance.

Strategic Initiatives

Coherus scored a big win with its announced divestiture of the Udenyca franchise for ~$483.4M upfront cash payment, giving the company the ability to largely eliminate debt from its balance sheet which has been the key overhang on shares.

Negative Factors

Earnings Report

Non-GAAP net loss of $0.28 per share in Q4 was worse than analyst forecast of $0.12 loss per share.

Market Competition

Risks include regulatory and clinical challenges, as some products are not approved, and competition in the market could impact pricing.

Revenue Performance

Q4 revenue was slightly below analyst estimates.

Coherus Biosciences Business Overview & Revenue Model

Company Description

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

How the Company Makes Money

Coherus BioSciences generates revenue primarily through the sale of its biosimilar products. The company's revenue model involves the development, manufacturing, and commercialization of biosimilars, which are essentially equivalent versions of existing biologic drugs that have lost patent protection. Key revenue streams include direct sales of these biosimilars to healthcare providers and distributors. Coherus also enters into strategic partnerships with other pharmaceutical companies to enhance its market reach and distribution capabilities, thereby contributing to its earnings. As patents of various branded biologics expire, Coherus capitalizes on these opportunities by introducing cost-effective biosimilar alternatives, thus driving its revenue growth.

Coherus Biosciences Financial Statement Overview

Summary

Coherus Biosciences faces financial challenges, notably a zero stockholders' equity which suggests financial instability. However, there's positive revenue growth and improvement in net profit margin, indicating potential recovery. Cash flow improvements are a positive sign, but operational cash flow remains a concern.

Income Statement

The income statement shows some challenges in profitability, with negative EBIT and EBITDA margins in recent years. However, there is a positive revenue growth trajectory from 2023 to TTM (Trailing-Twelve-Months), indicating potential recovery. Net profit margin has shifted to positive in TTM, suggesting improvements in cost management or other operational efficiencies.

Balance Sheet

The balance sheet highlights significant concerns, with zero stockholders' equity in TTM and a history of negative equity in previous years, indicating potential financial instability. The absence of total debt in TTM is a positive indicator, but the lack of equity is a major risk.

Cash Flow

Cash flow analysis shows improvement with a significant increase in investing cash flow and a reduction in negative free cash flow. Operating cash flow remains negative, which could be a risk if not addressed. However, the positive trajectory in free cash flow growth is a strength.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
266.96M	257.24M	211.04M	326.55M	475.82M
	Gross Profit
149.41M	94.46M	140.96M	268.96M	438.16M
	EBIT
-111.67M	-203.20M	-256.88M	-263.86M	156.32M
	EBITDA
60.94M	-193.94M	-255.58M	-260.69M	161.84M
	Net Income Common Stockholders
28.51M	-237.89M	-326.63M	-306.32M	132.24M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
125.99M	117.75M	191.68M	417.19M	541.16M
	Total Assets
448.53M	629.60M	480.85M	679.33M	841.65M
	Total Debt
231.51M	480.84M	471.06M	408.28M	404.02M
	Net Debt
105.53M	377.95M	407.51M	-8.91M	-137.13M
	Total Liabilities
580.52M	823.03M	618.26M	581.61M	560.67M
	Stockholders Equity
-131.99M	-193.43M	-137.42M	97.73M	280.97M
Cash Flow		Free Cash Flow
-20.44M	-175.17M	-243.16M	-38.72M	147.09M
	Operating Cash Flow
-20.44M	-174.88M	-241.12M	-37.43M	154.15M
	Investing Cash Flow
230.32M	144.64M	-166.85M	-138.41M	-14.40M
	Financing Cash Flow
-186.97M	69.60M	54.33M	51.88M	223.95M

Coherus Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.10
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CHRS, the sentiment is Positive. The current price of 1.1 is above the 20-day moving average (MA) of 0.97, above the 50-day MA of 0.97, and below the 200-day MA of 1.17, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 58.67 is Neutral, neither overbought nor oversold. The STOCH value of 52.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CHRS.

Coherus Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CHRS	57 Neutral	$127.49M	6.31	0.51%	―	3.78%	―
Sector *	52 Neutral	$5.35B	3.96	-42.60%	2.86%	17.58%	1.27%
SLS	43 Neutral	$164.51M	―	-4147.88%	―	―	60.51%
NAUT	41 Neutral	$85.45M	―	-30.93%	―	―	-1.20%
GNLX	35 Underperform	$99.24M	―	-130.58%	―	-95.29%	12.79%
TIL	34 Underperform	$94.97M	―	-37.51%	―	―	52.54%

Coherus Biosciences Corporate Events

Coherus Biosciences Board Member Stolper Steps Down

On April 22, 2025, Mark D. Stolper, a member of the Board of Directors at Coherus BioSciences, announced his decision not to stand for re-election at the company’s 2025 Annual Meeting of Stockholders. His departure is not due to any disagreements with the company, and he will continue to serve in a consulting role until the end of 2026. Following his decision, the board will reduce its size to nine directors. To ensure balanced representation among the board’s classes, on April 23, 2025, Rita A. Karachun and Michael Ryan were reclassified to different board classes, maintaining uninterrupted service while complying with the company’s Certificate of Incorporation.

Spark’s Take on CHRS Stock

According to Spark, TipRanks’ AI Analyst, CHRS is a Neutral.

Coherus Biosciences presents a mixed picture. Financial challenges, particularly a weak balance sheet, are significant concerns. However, strong revenue growth and strategic moves like the UDENYCA divestiture provide a positive outlook. Technical indicators suggest some upward momentum, and the low P/E ratio signals undervaluation. Positive developments in earnings calls and corporate events contribute to a moderate overall score.

To see Spark’s full report on CHRS stock, click here.

Coherus Biosciences CCO Resigns After UDENYCA Divestiture

Paul Reider, Coherus BioSciences’ Chief Commercial Officer, resigned effective April 30, 2025, following the company’s divestiture of its UDENYCA franchise. His departure is amicable, with no disagreements cited, and he will receive a compensation package including salary continuation and stock option extensions, while advising the company part-time until April 2026.

Spark’s Take on CHRS Stock

According to Spark, TipRanks’ AI Analyst, CHRS is a Neutral.

Coherus Biosciences presents a mixed picture. Financial challenges, particularly a weak balance sheet, are significant concerns. However, strong revenue growth and strategic moves like the UDENYCA divestiture provide a positive outlook. Technical indicators suggest some upward momentum, and the low P/E ratio signals undervaluation. Positive developments in earnings calls and corporate events contribute to a moderate overall score.

To see Spark’s full report on CHRS stock, click here.

Coherus Biosciences Completes UDENYCA Franchise Divestiture

On April 14, 2025, Coherus BioSciences announced the completion of its UDENYCA franchise divestiture to Intas Pharmaceuticals for up to $558.4 million. This strategic move, which included an upfront payment of $483.4 million, allows Coherus to focus on its oncology programs, reduce debt, and extend its cash runway into 2027, thereby strengthening its market position and operational focus on novel cancer therapies.

Spark’s Take on CHRS Stock

According to Spark, TipRanks’ AI Analyst, CHRS is a Neutral.

Coherus Biosciences shows promise with revenue growth and strategic initiatives, but financial instability and technical weakness present risks. The undervaluation based on P/E ratios represents potential upside if financial challenges are addressed. Earnings call sentiments were positive with a strong growth outlook, but investor perception challenges remain.

To see Spark’s full report on CHRS stock, click here.